-
CRI-Funded Study Highlights the Importance of Natural Killer Cells in Immunotherapy
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate…
-
Previewing the 2018 Rational Combinations 360 Conference
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14,…
-
First Immunotherapy Approved for Patients with Small Cell Lung Cancer
Nivolumab (Opdivo®) is now available for patients with metastatic and treatment-resistant small cell lung cancer
-
Former CRI Grantee Dr. Lieping Chen Named a “2018 Giant of Cancer Care in Immuno-Oncology”
Dr. Lieping Chen's work helped pave the way for the development of the PD-1/PD-L1 checkpoint immunotherapies that…
-
30 Days of CRI Impact: How Bacteria and Vaccines Can Help the Immune System Fight Cancer
This week’s breakthroughs highlight the benefits of bacteria, vaccines, and the use of immunotherapy earlier in the…
-
30 Days of CRI Impact: Getting to Know Your Cancer-Fighting Immune Cells
This week’s CRI-funded breakthroughs highlight the anti-tumor capabilities of T cells, macrophages, and natural killer cells.
-
30 Days of CRI Impact: Understanding Immune Checkpoints and Pathways
This week’s CRI breakthroughs deal with the development of checkpoint immunotherapy and other advances that have helped…
-
First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer
Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.
-
30 Days of CRI Impact: Laying the Foundation for Cancer Immunotherapy
The first nine days in June 2018 highlight early discoveries that helped establish cancer immunotherapy's foundations.
